Effect of Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine on Exacerbation Rate and Risk in Patients With Moderate to Severe COPD

By sjmartinez • February 13, 2025

Sciurba FC, Christenson SA, Rheault T, Bengtsson T, Rickard K, Barjaktarevic IZ. Effect of Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine on Exacerbation Rate and Risk in Patients With Moderate to Severe COPD. Chest. 2025 Feb;167(2):425-435. doi: 10.1016/j.chest.2024.07.168. Epub 2024 Aug 27. PMID: 39197510.

Tags: COPD, ensifentrine, exacerbation, patient-reported outcomes, Publications, Pulmonary, Critical Care & Sleep Medicine

Supporting Educational Excellence in Diversity (SEED): faculty development and allyship

Chadha P, Kang EH, Ngo V, Jorrin R, Kochai K, Ackerman-Barger K, Ton H. Supporting Educational Excellence in Diversity (SEED): faculty development and allyship. BMC[...]

Projected Mitigation of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B in the Gray Zone and the Immune-Tolerant Phase in the United States

Pak K, Sachar R, Saab S. Projected Mitigation of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B in the Gray Zone and the Immune-Tolerant Phase[...]

General movement assessments in neonates born with congenital gastrointestinal anomalies: a single site, retrospective study

Soumekh L, Bell S, Espinosa SL, Grogan T, Kesavan K, Calkins KL. General movement assessments in neonates born with congenital gastrointestinal anomalies: a single site,[...]